ACHIEVE-1 Study Shows Albuferon Non-Inferior To Pegasys; Questions Remain
This article was originally published in Pharmaceutical Approvals Monthly
With the March 9 release of the initial results of ACHIEVE-1, the final Phase III trial of Human Genome Sciences/Novartis' pegylated interferon Albuferon, Wall Street analysts have started to question the hepatitis C drug's market value. The trial failed to deliver outstanding efficacy results, and showed some signs of safety problems
You may also be interested in...
The dosing advantage for Novartis/Human Genome Sciences' follow-on interferon product Albuferon is enough to establish the hepatitis C therapy over Roche's go-to treatment Pegasys, according to a physician panel at the BIO CEO conference - quelling concerns that less frequent dosing might not be enough to get practitioners to switch to the new product
Lower 900 mcg dose of albinterferon alfa-2b is on track for hepatitis C filing in fall 2009, Human Genome Sciences says.
Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.